All In Biotech

NDA 209939 · Merck Sharp Dohme

Prevymis

Letermovir · Oral · Cytomegalovirus DNA Terminase Complex Inhibitor

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jan 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Nov 8, 2017

Approved uses

5

Original approval plus efficacy supplements

Registered trials

51

13 Phase 3, 16 recruiting

FAERS reports

3,257

2,664 serious, 588 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 14, 2026.

PREVYMIS is a CMV DNA terminase complex inhibitor indicated for: Prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). ( 1.1 ) Prophylaxis of CMV disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]). ( 1.2 ) 1.1 CMV Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients PREVYMIS ® is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). 1.2 CMV Prophylaxis in Kidney Transplant Recipients PREVYMIS is indicated for prophylaxis of CMV disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).

Mechanism: PREVYMIS is an antiviral drug against CMV [see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 30, 2024 Supplement 13 · Efficacy · priority review OrphanLabelLetter
  • Aug 30, 2024 Supplement 16 · Efficacy · priority review OrphanLabelLetter
  • Aug 2, 2023 Supplement 11 · Efficacy OrphanLabel
  • Jun 5, 2023 Supplement 12 · Efficacy · priority review OrphanLetterLabel
  • Nov 8, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
2 products under this application
  • PREVYMIS · LETERMOVIR 480MG · TABLET, ORAL · Prescription
  • PREVYMIS · LETERMOVIR 240MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Letermovir" as an intervention, any sponsor and status, largest first.

All 51 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use718
  • drug ineffective295
  • cytomegalovirus infection reactivation260
  • death196
  • acute kidney injury178
  • cytomegalovirus infection173
  • drug interaction166
  • product use in unapproved indication165
  • pancytopenia153
  • drug resistance99
  • hospitalisation99
  • pyrexia99

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
201882
2019257
2020272
2021395
2022379
2023413
2024503
2025557
2026398

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Prevymis* (Letermovir)

2024 spending

$120M

Beneficiaries

3,884

16,441 claims

Per beneficiary

$31,012

$252.09 per unit

View as table
YearSpending
2020$28,098,445
2021$38,109,251
2022$48,827,212
2023$73,949,062
2024$120,450,531

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 39 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.